Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-101 long-term extension in pulmonary arterial hypertension
CTR20233276Phase 3Terminated
- Sponsor
- Aerovate Therapeutics
- Start
- Oct 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of 4-chlorokynurenine in pulmonary arterial hypertension (PAH), sponsored by Aerovate Therapeutics. Started Oct 2023; status: terminated.
02
Drugs
4-chlorokynurenine
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on CTR20233276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233276.